Connection
Michael Birrer to Antineoplastic Agents
This is a "connection" page, showing publications Michael Birrer has written about Antineoplastic Agents.
|
|
Connection Strength |
|
|
|
|
|
3.935 |
|
|
|
-
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecol Oncol. 2023 05; 172:82-91.
Score: 0.487
-
Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Oncologist. 2019 04; 24(4):425-429.
Score: 0.364
-
Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703.
Score: 0.344
-
Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087.
Score: 0.323
-
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.
Score: 0.316
-
Birrer MJ. Ovarian cancer: targeting the untargetable. Am Soc Clin Oncol Educ Book. 2014; 13-5.
Score: 0.257
-
Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011 Jan 01; 29(1):69-75.
Score: 0.207
-
Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010 May; 117(2):248-54.
Score: 0.197
-
Farley J, Birrer MJ. Novel therapeutic targets. Cancer Treat Res. 2009; 149:63-84.
Score: 0.182
-
Chi RA, van der Watt P, Wei W, Birrer MJ, Leaner VD. Inhibition of Kpn?1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer. 2021 Feb 02; 21(1):106.
Score: 0.105
-
Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 1998 Apr 15; 90(8):597-605.
Score: 0.086
-
Szabo E, Francis J, Birrer MJ. Alterations in differentiation and apoptosis induced by bufalin in cJun overexpressing U-937 cells. Int J Oncol. 1998 Feb; 12(2):403-9.
Score: 0.085
-
Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstet Gynecol. 2017 03; 129(3):439-447.
Score: 0.080
-
Xiao H, Qi R, Li T, Awuah SG, Zheng Y, Wei W, Kang X, Song H, Wang Y, Yu Y, Bird MA, Jing X, Yaffe MB, Birrer MJ, Ghoroghchian PP. Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. J Am Chem Soc. 2017 03 01; 139(8):3033-3044.
Score: 0.080
-
McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Jan; 144(1):101-106.
Score: 0.078
-
Smith LM, Birrer MJ. Use of transcription factors as agents and targets for drug development. Oncology (Williston Park). 1996 Oct; 10(10):1532-8; discussion 1541-2.
Score: 0.078
-
Wilbur MB, Birrer MJ, Spriggs DR. CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):177-9.
Score: 0.077
-
Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli KR, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, Birrer MJ. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol. 2016 Mar; 2(3):370-2.
Score: 0.075
-
van der Watt PJ, Chi A, Stelma T, Stowell C, Strydom E, Carden S, Angus L, Hadley K, Lang D, Wei W, Birrer MJ, Trent JO, Leaner VD. Targeting the Nuclear Import Receptor Kpn?1 as an Anticancer Therapeutic. Mol Cancer Ther. 2016 04; 15(4):560-73.
Score: 0.074
-
Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget. 2015 Dec 29; 6(42):44551-62.
Score: 0.074
-
Ye H, Tanenbaum LM, Na YJ, Mantzavinou A, Fulci G, Del Carmen MG, Birrer MJ, Cima MJ. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J Control Release. 2015 Dec 28; 220(Pt A):358-367.
Score: 0.073
-
Penson RT, Dizon DS, Birrer MJ. Clear cell cancer of the ovary. Curr Opin Oncol. 2013 Sep; 25(5):553-7.
Score: 0.063
-
Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer. 2011 May; 21(4):763-70.
Score: 0.053
-
Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 01; 11(17):6300-10.
Score: 0.036
-
Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, Brown D, Gardner GJ, Birrer MJ, Benbrook DM. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007.
Score: 0.032
-
Mirza MR, Bergmann TK, Mau-S?rensen M, Christensen RD, ?vall-Lundqvist E, Birrer MJ, J?rgensen M, Roed H, Malander S, Nielsen F, Lassen U, Br?sen K, Bj?rge L, M?enp?? J. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019 10; 84(4):791-798.
Score: 0.024
-
Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 12 18; 8(1):2166.
Score: 0.021
-
Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem. 1997 May 30; 272(22):14041-4.
Score: 0.020
-
Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb; 136(2):246-53.
Score: 0.017
-
Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One. 2012; 7(2):e30550.
Score: 0.014
-
Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|